Trevena (TRVN) Stock Price, News & Analysis

Company Overview

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Key Stats

• Today's Range: $1.39 to $1.40
• 50-Day Range: $1.28 to $1.86
• 52-Week Range: $1.13 to $12.25
• Volume: 380 shs
• Average Volume: 2,688 shs
• Market Capitalization: $1.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

TRVN Stock Analysis - Frequently Asked Questions

How have TRVN shares performed this year?

Trevena's stock was trading at $1.50 at the beginning of 2025. Since then, TRVN shares have decreased by 7.3% and is now trading at $1.39.
View the best growth stocks for 2025 here.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($9.25) by $9.02. The biopharmaceutical company earned $0.33 million during the quarter.

When did Trevena's stock split?

Trevena's stock reverse split on Tuesday, August 13th 2024. The 1-25 reverse split was announced on Thursday, August 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Trevena's major shareholders?

Top institutional investors of Trevena include Concourse Financial Group Securities Inc..
View institutional ownership trends.

How do I buy shares of Trevena?

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Trevena own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevena investors own include Novavax (NVAX), Conatus Pharmaceuticals (CNAT), Sorrento Therapeutics (SRNE), NIO (NIO), TherapeuticsMD (TXMD), Cara Therapeutics (CARA) and SCYNEXIS (SCYX).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 3/25/2025
• Next Earnings (Estimated): 4/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRVN
• CIK: 1429560
• Web: www.trevena.com
• Phone: (610) 354-8840
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +259.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($47.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-40,290,000.00
• Net Margins: N/A
• Pretax Margin: -6,222.30%
• Return on Equity: N/A
• Return on Assets: -119.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.42
• Quick Ratio: 2.42

Sales & Book Value

• Annual Sales: $443,000.00
• Price / Sales: 2.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($11.07) per share
• Price / Book: -0.13

Miscellaneous

• Outstanding Shares: 864,000
• Free Float: 841,000
• Market Cap: $1.20 million
• Optionable: Optionable
• Beta: 1.05